Alpha Tau Medical shareholders approve CEO Sofer to remain board chair

• Alpha Tau Medical held its annual shareholder meeting on June 23, 2026.
• Shareholders backed the re-election of David Milch, Ruth Alon as Class II directors, with terms running through the 2029 annual meeting.
• Investors re-approved the executive officer and director compensation policy.
• Shareholders endorsed Uzi Sofer continuing as board chairman, with a separate compensation package also adopted.
• Holders authorized extending certain director and officer option terms, with Kost Forer Gabbay & Kasierer reappointed as independent auditor for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-072034), on June 25, 2026, and is solely responsible for the information contained therein.